NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
Clinical Trials
10 trialsNCT07076550 2026-03-16
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Alpha-9 Oncology USA Inc.
Phase 1 Recruiting
NCT07364474 2026-03-11
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Massachusetts General Hospital
Phase NA Recruiting
NCT04792463 2026-03-09
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
Recruiting
NCT06246149 2026-03-04
ATOM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT06414590 2026-03-03
Neoadjuvant Tebentafusp for Uveal Melanoma
Thomas Jefferson University
Phase 2 Recruiting
NCT04855435 2026-03-02
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
MonTa Biosciences ApS
Phase 1 Recruiting
NCT06007690 2026-03-02
CoMpass
Aura Biosciences
Phase 3 Recruiting
NCT06070012 2026-02-27
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT07421739 2026-02-19
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
Aura Biosciences
Recruiting